Publications

Detailed Information

A hospital-based case-control study of identifying ovarian cancer using symptom index

DC Field Value Language
dc.contributor.authorKim, Mi-Kyung-
dc.contributor.authorKim, Kidong-
dc.contributor.authorKim, Sun Min-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorSong, Yong-Sang-
dc.contributor.authorKang, Soon-Beom-
dc.contributor.authorPark, Noh-Hyun-
dc.date.accessioned2012-06-04T01:29:18Z-
dc.date.available2012-06-04T01:29:18Z-
dc.date.issued2009-12-
dc.identifier.citationJOURNAL OF GYNECOLOGIC ONCOLOGY; Vol.20 4; 238-242ko_KR
dc.identifier.issn2005-0380-
dc.identifier.urihttps://hdl.handle.net/10371/76747-
dc.description.abstractObjective: Recently, a symptom index for identification of ovarian cancer, based on specific symptoms along with their frequency and duration, was proposed. The current study aimed at validation of this index in Korean population. Methods: A case-control study of 116 women with epithelial ovarian cancer and 209 control women was conducted using questionnaires on eight symptoms. These included pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, difficulty eating/feeling full. The symptom index was considered positive if any of the 8 symptoms present for < 1 year that occurred > 12 times per month. The symptoms were compared between ovarian cancer group and control group using chi-square test. Logistic regression analysis was used to determine whether the index predicted cancer. Sensitivity and specificity of the symptom index were also determined. Results: The symptom index was positive in 65.5% of women with ovarian cancer, in 31.1% of women with benign cysts, and in 6.7% of women on routine screening (ps < 0.001). Significantly higher proportion of ovarian cancer patients were positive for each symptom as compared with control group (ps < 0.001). Results from the logistic regression indicated that the symptom index independently predicted cancer (p < 0.001; OR, 10.51; 95% Cl, 6.14 to 17.98). Overall, the sensitivity and specificity of the symptom index were 65.5% and 84.7%, respectively. Analyses of sensitivity by stage showed that the index was positive in 44.8% of patients with stage I/II disease and in 72.9% of patients with stage III/IV disease. Conclusion: The current study supported previous studies suggesting that specific symptoms were useful in identifying women with ovarian cancer.ko_KR
dc.description.sponsorshipThis study was supported by a grant from the National R&D Program for
Cancer Control, Ministry for Health, Welfare and Family affairs, Republic
of Korea (0920010).
ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPYko_KR
dc.subjectOvarian cancerko_KR
dc.subjectSymptomsko_KR
dc.subjectEarly diagnosisko_KR
dc.subjectCase-control studyko_KR
dc.titleA hospital-based case-control study of identifying ovarian cancer using symptom indexko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김미경-
dc.contributor.AlternativeAuthor김기동-
dc.contributor.AlternativeAuthor김선민-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor강순범-
dc.identifier.doi10.3802/jgo.2009.20.4.238-
dc.citation.journaltitleJOURNAL OF GYNECOLOGIC ONCOLOGY-
dc.description.citedreferenceHamilton W, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2998-
dc.description.citedreferenceMenon U, 2009, LANCET ONCOL, V10, P327, DOI 10.1016/S1470-2045(09)70026-9-
dc.description.citedreferenceAndersen MR, 2008, CANCER-AM CANCER SOC, V113, P484, DOI 10.1002/cncr23577-
dc.description.citedreferenceGoff BA, 2007, CANCER, V109, P221, DOI 10.1002/cncr.22371-
dc.description.citedreference2007, LANCET, V369, P2051-
dc.description.citedreferenceOlivier RI, 2006, GYNECOL ONCOL, V100, P20, DOI 10.1016/j.ygyno.2005.08.038-
dc.description.citedreferenceFriedman GD, 2005, FAM PRACT, V22, P548, DOI 10.1093/fampra/cmi044-
dc.description.citedreferenceLataifeh I, 2005, AUST NZ J OBSTET GYN, V45, P211-
dc.description.citedreferenceYawn BP, 2004, MAYO CLIN PROC, V79, P1277-
dc.description.citedreferenceGoff BA, 2004, JAMA-J AM MED ASSOC, V291, P2705-
dc.description.citedreferenceWebb PM, 2004, GYNECOL ONCOL, V92, P232, DOI 10.1016/j.ygyno.2003.09.005-
dc.description.citedreferenceVine MF, 2003, GYNECOL ONCOL, V90, P75, DOI 10.1016/S0090-8258(03)00175-6-
dc.description.citedreferencePARKIN DM, 2002, CA CANC J CLIN, V55, P74-
dc.description.citedreferenceOlson SH, 2001, OBSTET GYNECOL, V98, P212-
dc.description.citedreferenceGoff BA, 2000, CANCER, V89, P2068-
dc.description.citedreferenceEltabbakh GH, 1999, GYNECOL ONCOL, V75, P476-
dc.description.citedreferenceJacobs IJ, 1999, LANCET, V353, P1207-
dc.description.citedreferenceJACOBS I, 1993, BRIT MED J, V306, P1030-
dc.description.citedreferenceSMITH EM, 1985, CANCER, V56, P2727-
dc.description.tc8-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share